2nd Dermatology Department, Aristotle University School of Medicine, Thessaloniki, Greece.
J Dermatolog Treat. 2013 Jun;24(3):162-8. doi: 10.3109/09546634.2011.646939. Epub 2012 Jan 4.
Anti-tumor necrosis factor (TNF) agents' effect on psoriatic nails is still under investigation.
To evaluate the therapeutic potentials of anti-TNF agents on psoriatic nails of patients suffering from moderate-to-severe plaque psoriasis.
A retrospective study was conducted based on the medical records of 12 patients treated with infliximab, 14 with adalimumab and 13 with etanercept in daily practice. The Nail Psoriasis Severity Index (NAPSI) was recorded at baseline, week 12, 24 and 48.
At week 12, NAPSI was improved compared to baseline by 48.0% (range: 40.2-66.6%) with infliximab, 35.0% (range: 25.0-52.6%) with adalimumab and 41.7% (range: 39.5-46.4%) with etanercept. At week 24, NAPSI was improved by 80.4% (range: 66.6-90.2%) with infliximab, 70.2% (66.6-80.2%) with adalimumab and 76.1% (62.5-85.5%) with etanercept. At week 48, NAPSI was improved by 95.1% (range: 89.5-97.3%) with infliximab, 89.5% (75.0-94.8%) with adalimumab and 92.8% (84.3-96.0%) with etanercept. NAPSI percentage improvement was statistically significant across follow-up period (p = 0.000) for each anti-TNF treatment, as well as among treatments at all time points (week 12, p = 0.000; week 24, p = 0.001; week 48, p = 0.000).
All anti-TNF agents result in a significant improvement of NAPSI score, with infliximab given the precedence and followed by etanercept and adalimumab.
抗肿瘤坏死因子（TNF）药物对银屑病指甲的疗效仍在研究中。
评估抗 TNF 药物治疗中重度斑块型银屑病患者银屑病指甲的治疗潜力。
对在日常实践中接受英夫利昔单抗治疗的 12 例、阿达木单抗治疗的 14 例和依那西普治疗的 13 例患者的病历进行回顾性研究。在基线、第 12、24 和 48 周记录指甲银屑病严重程度指数（NAPSI）。
与基线相比，英夫利昔单抗治疗第 12 周 NAPSI 改善 48.0%（范围：40.2-66.6%），阿达木单抗治疗改善 35.0%（范围：25.0-52.6%），依那西普治疗改善 41.7%（范围：39.5-46.4%）。第 24 周时，英夫利昔单抗治疗 NAPSI 改善 80.4%（范围：66.6-90.2%），阿达木单抗治疗改善 70.2%（范围：66.6-80.2%），依那西普治疗改善 76.1%（范围：62.5-85.5%）。第 48 周时，英夫利昔单抗治疗 NAPSI 改善 95.1%（范围：89.5-97.3%），阿达木单抗治疗改善 89.5%（范围：75.0-94.8%），依那西普治疗改善 92.8%（范围：84.3-96.0%）。在整个随访期间，NAPSI 的百分比改善在每个抗 TNF 治疗中均具有统计学意义（p = 0.000），而且在所有时间点（第 12 周、第 24 周和第 48 周）治疗之间也具有统计学意义（p = 0.000）。
所有抗 TNF 药物均能显著改善 NAPSI 评分，英夫利昔单抗效果最佳，其次是依那西普和阿达木单抗。
